Patents by Inventor Xiaopeng Mo

Xiaopeng Mo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations Thereof
    Publication number: 20210309642
    Abstract: The invention relates to solid forms of certain N-(pyrimidinyloxy)acrylamide derivatives that are useful in the treatment of proliferation and immunological disorders and other diseases related to the dysregulation of kinases including EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK. The invention provides methods of making these materials and their salts and polymorphs, and intermediates for preparing these materials, as well as pharmaceutical compositions comprising these materials. The solid forms and pharmaceutical compositions comprising them are useful to treat conditions including a proliferation disorder, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye, rheumatoid arthritis, or lupus.
    Type: Application
    Filed: August 9, 2018
    Publication date: October 7, 2021
    Applicants: ACEA Therapeutics, Inc., HANGZHOU ACEA PHARMACEUTICAL RESEARCH CO., LTD., ZHEJIANG ACEA PHARMACEUTICALS CO., LTD.
    Inventors: Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kunhua DONG, Liang CHEN, Bojie WENG, Xiaopeng MO, Kongen DAI, Yimei BAO, Jian WU, Bin LIANG, Guanglin ZHOU, Zhen WANG
  • Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
    Patent number: 10533011
    Abstract: Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 14, 2020
    Assignee: ACEA THERAPEUTICS, INC.
    Inventors: Long Mao, Jia Liu, Yile Chen, Yuning Hua, Kongen Dai, Yimei Bao, Bojie Weng, Xiaopeng Mo, Jian Wu, Xiao Xu, Wanhong Xu, Xiaobo Wang
  • PHARMACEUTICAL SALTS, PHYSICAL FORMS, AND COMPOSITIONS OF PYRROLOPYRIMIDINE KINASE INHIBITORS, AND METHODS OF MAKING SAME
    Publication number: 20180312510
    Abstract: Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.
    Type: Application
    Filed: June 30, 2016
    Publication date: November 1, 2018
    Applicant: ACEA THERAPEUTICS, INC.
    Inventors: Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kongen DAI, Yimei BAO, Bojie WENG, Xiaopeng MO, Jian WU, Xiao XU, Wanhong XU, Xiaobo WANG
  • Synthetic process for anticancer drug fluorapacin and trisulfide derivatives
    Patent number: 7851657
    Abstract: The invention provides a synthetic and manufacturing process for the preparation of the anticancer drug, fluorapacin, bis(4-fluorobenzyl)trisulfide, and related trisulfide derivatives on large scale. Also provided are processes for the purification and isolation of fluorapacin having high purity and improved stability.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: December 14, 2010
    Assignee: Acea Biosciences, Inc.
    Inventors: Haoyun An, Xiaopeng Mo
  • SYNTHETIC PROCESS FOR ANTICANCER DRUG FLUORAPACIN AND TRISULFIDE DERIVATEVES
    Publication number: 20100191016
    Abstract: The invention provides a synthetic and manufacturing process for the preparation of the anticancer drug, fluorapacin, bis(4-fluorobenzyl)trisulfide, and related trisulfide derivatives on large scale. Also provided are processes for the purification and isolation of fluorapacin having high purity and improved stability.
    Type: Application
    Filed: March 27, 2009
    Publication date: July 29, 2010
    Applicant: ACEA BIOSCIENCES, INC.
    Inventors: Haoyun An, Xiaopeng Mo